Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of “Moderate Buy” from Analysts

Pfizer Inc. (NYSE:PFE) has received a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, three have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $29.17.

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th.

Institutional Investors Weigh In On Pfizer

Several hedge funds have recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC bought a new stake in Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth about $27,000. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth about $28,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $24.30 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business has a fifty day simple moving average of $23.42 and a two-hundred day simple moving average of $24.85. Pfizer has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $138.18 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the business posted $0.82 earnings per share. On average, analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.08%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.